Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Breast 1

Conditions

Triple Negative Breast Neoplasms 16Carcinoma, Non-Small-Cell Lung 7Pancreatic Neoplasms 6Melanoma 6Breast Neoplasms 6Carcinoma, Renal Cell 5Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Ovarian Neoplasms 2Neoplasms 2Liver Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Anus Neoplasms 2Adenocarcinoma of Lung 2Adenocarcinoma Of Esophagus 2Adenocarcinoma 2Uveal Melanoma 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

spartalizumab 1fludarabine 1Mass Spectrometry 1Cyclophosphamide 1Chromatography, High Pressure Liquid 1BI 2536 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma, Alveolar Soft Part × spartalizumab × Breast × Clear all
NCT02936102 2025-11-14

A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

Novartis

Phase 1 Terminated
154 enrolled
BreastSarcoma

Chordoma, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡